News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 4.7.
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung Cancer
The Journal of Clinical Oncology has published the final efficacy and safety results from the phase I/II ARROW trial evaluating pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer. Pralsetinib is a selective RET kinase inhibitor designed for the subset of NSCLC patients harboring RET gene fusions, which occur in approximately 1-2% of cases. The final data from this…
[Articles] Lymph node surgery and CDK4/6 inhibitors in early breast cancer: a pooled analysis from five randomised trials
A pooled analysis of five randomised trials, published in The Lancet Oncology, evaluated whether performing sentinel lymph node biopsy (SLNB) or complete axillary lymph node dissection (cALND) solely to determine eligibility for CDK4/6 inhibitor therapy is justified in early breast cancer. The researchers found that the number needed to diagnose and treat was very high, the procedures added substa…
[Articles] Estimating global cancer survival and mortality from 1990 to 2050: a simulation-based analysis of 17 cancers
A major modeling study published in The Lancet Oncology projects global cancer survival and mortality trends across 17 cancer types from 1990 to 2050, providing country-level estimates. The analysis accounts for demographic shifts, epidemiological trends, health system barriers, and workforce constraints. The findings reveal that large disparities in cancer survival between countries are expected …
Systemic induction therapy and the expanding frontier of bladder preservation in MIBC
A review published in Nature Reviews Clinical Oncology examines two recent phase II trials, INDIBLADE and SURE-02, which explore whether systemic induction therapy can enable bladder preservation in patients with muscle-invasive bladder cancer (MIBC). Traditionally, radical cystectomy or radiotherapy has been the standard of care for MIBC, but increasingly effective systemic regimens are raising t…
The sleeping threat: targeting cancer dormancy to transform metastasis therapy
A comprehensive review published in Nature Reviews Cancer synthesizes the latest understanding of how disseminated cancer cells enter and maintain dormancy before triggering metastatic relapse. The paper examines how microenvironmental cues, epigenetic programs, and immune system interactions collectively govern the behavior of dormant cancer cells scattered throughout the body. Importantly, the r…
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study
The Phase III LEAP-010 trial, published in the Journal of Clinical Oncology, evaluated whether adding the multi-kinase inhibitor lenvatinib to pembrolizumab improves outcomes in patients with PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma treated in the first-line setting. The study compared pembrolizumab plus lenvatinib against pembrolizumab plus placebo, with overal…
[News] 2026 Society of Surgical Oncology Annual Meeting
At the 2026 Society of Surgical Oncology Annual Meeting, Martin Heidinger presented results from a preplanned analysis of the TAXIS/OPBC-03 phase 3 trial, which evaluated tailored axillary surgery (TAS) as an alternative to standard axillary lymph node dissection (ALND) in patients with node-positive breast cancer. The trial investigated whether reducing axillary tumour burden through a less radic…
Reliable detection of Host-Microbe Signatures in cancer using PRISM
Researchers led by Ghaddar et al. have developed PRISM, a new computational framework designed to accurately identify microbial organisms and remove contamination artifacts from human cancer genomic data. By applying PRISM to two of the largest cancer genomics repositories — The Cancer Genome Atlas (TCGA) and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) — the team uncovered robust host…
Knowledge-enhanced pretraining for vision-language pathology foundation model on cancer diagnosis
Researchers led by Zhou et al. have developed KEEP, a knowledge-enhanced foundation model that integrates structured disease knowledge into vision-language pretraining for computational pathology. Published in the prestigious journal Cancer Cell, the approach combines curated medical knowledge graphs with large-scale pathology image-text datasets to improve AI-driven cancer diagnosis. The model de…
A recipe for chaos: Extrachromosomal DNA and the hallmarks of cancer
A major review published in Cell by Wong et al. examines how extrachromosomal DNA (ecDNA) — oncogenic genetic elements that detach from chromosomes — drives genomic instability and accelerated tumor evolution. The authors detail the mechanistic basis by which ecDNA escapes Mendelian inheritance rules, enabling rapid amplification of cancer-driving genes and fostering intratumor heterogeneity. The …